

Results of Annual General Meeting

In accordance with ASX Listing Rule 3.13.2 & section 251AA of the Corporations Act, the following information is provided to the ASX in relation to the resolutions passed by the shareholders of Genetic Technologies Limited ('Company'), at its Annual General Meeting of shareholders held on 28 November 2019.

All resolutions put to the meeting were passed on a show of hands. The Company received 819,337,079 valid proxy votes in respect of each resolution. The Chairman voted all undirected proxies held at his discretion in favour of each resolution. The instructions given to validly appointed proxies in respect of the resolutions were as follows:

Resolution	For	Against	Abstain	Chairman's Discretion	Excluded
1. Adopt Remuneration Report	249,682,922	22,860,356	1,031,764	3,840,085	541,921,952
2. Elect Nick Burrows	803,100,995	11,309,106	1,323,093	3,603,885	0
3. Re-Elect Peter Rubinstein	798,438,368	16,149,122	1,309,504	3,440,085	0
4. Approve Increased Placement Capacity	796,050,739	18,798,441	1,047,814	3,440,085	0
5. Approve Sub Underwriting Options to Mr Rubinstein	348,877,514	25,163,756	427,376,346	9,594,200	8,325,263
6. Approve Sub Underwriting Options to Dr Muchnicki	357,866,648	24,334,496	433,630,461	3,505,474	0
7. Approve of Name Change	785,317,301	21,522,621	9,157,072	3,340,085	0
8. Approve Proposed Placement	791,577,330	22,539,704	1,606,622	3,613,423	0

Justyn Stedwell
Company Secretary

About Genetic Technologies Limited

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company's lead products **GeneType for Breast Cancer** for non-hereditary breast cancer and **GeneType for Colorectal Cancer** are clinically validated risk assessment tests and are first in class.

Genetic Technologies is developing a pipeline of risk assessment products.

For more information, please visit www.gtglabs.com